Ocera Therapeutics Inc. (NASDAQ:OCRX) shares were up 21% on Thursday . The stock traded as high as $2.56 and last traded at $2.48, with a volume of 77,798 shares changing hands. The stock had previously closed at $2.05.

Several research analysts have recently weighed in on OCRX shares. Brean Capital reissued a “buy” rating on shares of Ocera Therapeutics in a report on Tuesday, April 12th. Zacks Investment Research upgraded shares of Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research report on Wednesday, May 4th.

The firm’s market capitalization is $53.91 million. The stock’s 50 day moving average is $2.30 and its 200 day moving average is $2.76.

Ocera Therapeutics (NASDAQ:OCRX) last released its quarterly earnings results on Friday, April 29th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.03. Equities research analysts predict that Ocera Therapeutics Inc. will post ($1.39) EPS for the current fiscal year.

A hedge fund recently raised its stake in Ocera Therapeutics stock. Turner Investments L.P. boosted its position in shares of Ocera Therapeutics Inc. (NASDAQ:OCRX) by 29.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 673,487 shares of the biopharmaceutical company’s stock after buying an additional 152,210 shares during the period. Turner Investments L.P. owned 3.28% of Ocera Therapeutics worth $2,101,000 as of its most recent filing with the SEC.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.